884
Views
57
CrossRef citations to date
0
Altmetric
Review Articles

Lipid-based nanoformulations in the treatment of neurological disorders

, , , , , , , , , & show all
Pages 185-204 | Received 11 Sep 2019, Accepted 03 Feb 2020, Published online: 02 Mar 2020

References

  • Abdelbary G, Fahmy RH. 2009. Diazepam-loaded solid lipid nanoparticles: design and characterization. AAPS PharmSciTech. 10(1):211–219.
  • Ahmad N, Ahmad R, Alam MA, Ahmad FJ, Amir M, Pottoo FH, Sarafroz M, Jafar M, Umar K. 2019. Daunorubicin oral bioavailability enhancement by surface coated natural biodegradable macromolecule chitosan based polymeric nanoparticles. Int J Biol Macromol. 128:825–838.
  • Alam MI, Baboota S, Ahuja A, Ali M, Ali J, Sahni JK. 2013. Intranasal infusion of nanostructured lipid carriers (NLC) containing CNS acting drug and estimation in brain and blood. Drug Deliv. 20(6):247–251.
  • Alam MS, Garg A, Pottoo FH, Saifullah MK, Tareq AI, Manzoor O, Mohsin M, Javed MN. 2017. Gum ghatti mediated, one pot green synthesis of optimized gold nanoparticles: Investigation of process-variables impact using Box-Behnken based statistical design. Int J Biol Macromol. 104:758–767.
  • Alam MS, Javed MN, Pottoo FH, Waziri A, Almalki FA, Hasnain MS, Garg A, Saifullah MK. n.d. QbD approached comparison of reaction mechanism in microwave synthesized gold nanoparticles and their superior catalytic role against hazardous nirto-dye. Appl Organometal Chem. 0:e5071.
  • Alam T, Pandit J, Vohora D, Aqil M, Ali A, Sultana Y. 2015. Optimization of nanostructured lipid carriers of lamotrigine for brain delivery: in vitro characterization and in vivo efficacy in epilepsy. Expert Opin Drug Deliv. 12(2):181–194.
  • Ali Khan A, Mudassir J, Mohtar N, Darwis Y. 2013. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int J Nanomed. 8:2733–2744.
  • Barkat MA, Beg S, Pottoo FH, Ahmad FJ. 2019. Nanopaclitaxel therapy: an evidence based review on the battle for next-generation formulation challenges. Nanomedicine (Lond). 14(10):1323–1341.
  • Barkat MA, Harshita FN, Beg S, Pottoo FH, Garg A, Singh SP, Ahmad FJ. 2019. Silver nanoparticles and their antimicrobial applications. CNANOM. 8(3):215–224.
  • Battaglia L, Serpe L, Foglietta F, Muntoni E, Gallarate M, Rodriguez ADP, Solinis MA. 2016. Application of lipid nanoparticles to ocular drug delivery. Expert Opinion Drug Deliv. 13(12):1743–1757.
  • Birbeck GL. 2010. Epilepsy care in developing countries: part I of II. Epilepsy Curr. 10(4):75–79.
  • Bodor n, Buchwald n. 1999. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv Drug Deliv Rev. 36(2–3):229–254.
  • Bondi ML, Montana G, Craparo EF, Picone P, Capuano G, Carlo MD, Giammona G. 2009. Ferulic acid-loaded lipid nanostructures as drug delivery systems for Alzheimer’s disease: preparation, characterization and cytotoxicity studies. Curr Nanosci. 5(1):26–32.
  • Bramini M, Ye D, Hallerbach A, Nic Raghnaill M, Salvati A, Åberg C, Dawson KA. 2014. Imaging approach to mechanistic study of nanoparticle interactions with the blood–brain barrier. ACS Nano. 8(5):4304–4312.
  • Castellani RJ, Rolston RK, Smith MA. 2010. Alzheimer disease. Dis Mon. 56(9):484–546.
  • Chan H-K, Kwok PCL. 2011. Production methods for nanodrug particles using the bottom-up approach. Adv Drug Deliv Rev. 63(6):406–416.
  • Chen H, Yoshioka H, Kim GS, Jung JE, Okami N, Sakata H, Maier CM, Narasimhan P, Goeders CE, Chan PH. 2011. Oxidative stress in ischemic brain damage: mechanisms of cell death and potential molecular targets for neuroprotection. Antioxid Redox Signal. 14(8):1505–1517.
  • Chen X, Pan W. 2015. The treatment strategies for neurodegenerative diseases by integrative medicine. Integr Med Int. 1(4):223–225.
  • Cingolani GM, Di Stefano A, Mosciatti B, Napolitani F, Giorgioni G, Ricciutelli M, Claudi F. 2000. Synthesis of L-(+)-3-(3-hydroxy-4-pivaloyloxybenzyl)-2,5-diketomorpholine as potential prodrug of L-dopa. Bioorg Med Chem Lett. 10(12):1385–1388.
  • Connolly BS, Lang AE. 2014. Pharmacological treatment of Parkinson disease: a review. JAMA. 311(16):1670–1683.
  • Daneman R, Prat A. 2015. The blood–brain barrier. Cold Spring Harb Perspect Biol. 7(1):a020412.
  • Dauer W, Przedborski S. 2003. Parkinson’s disease: mechanisms and models. Neuron. 39(6):889–909.
  • Deb P, Sharma S, Hassan KM. 2010. Pathophysiologic mechanisms of acute ischemic stroke: an overview with emphasis on therapeutic significance beyond thrombolysis. Pathophysiology. 17(3):197–218.
  • Debnath SK, Saisivam S, Debanth M, Omri A. 2018. Development and evaluation of Chitosan nanoparticles based dry powder inhalation formulations of prothionamide. PLOS One. 13(1):e0190976.
  • Dehouck B, Fenart L, Dehouck MP, Pierce A, Torpier G, Cecchelli R. 1997. A new function for the LDL receptor: transcytosis of LDL across the blood-brain barrier. J. Cell Biol. 138(4):877–889.
  • Engelborghs S, D'Hooge R, De Deyn PP. 2000. Pathophysiology of epilepsy. Acta Neurol Belg. 100(4):201–213.
  • Eskandari S, Varshosaz J, Minaiyan M, Tabbakhian M. 2011. Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model. Int J Nanomed. 6:363–371.
  • Esposito E, Fantin M, Marti M, Drechsler M, Paccamiccio L, Mariani P, Sivieri E, Lain F, Menegatti E, Morari M, et al. 2008. Solid lipid nanoparticles as delivery systems for bromocriptine. Pharm Res. 25(7):1521–1530.
  • Ezzati Nazhad Dolatabadi J, Omidi Y. 2016. Solid lipid-based nanocarriers as efficient targeted drug and gene delivery systems. Trac Trends Anal Chem. 77:100–108.
  • Fatouh AM, Elshafeey AH, Abdelbary A. 2017. Intranasal agomelatine solid lipid nanoparticles to enhance brain delivery: formulation, optimization and in vivo pharmacokinetics. DDDT. 11:1815–1825.
  • Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J, Forsgren L, French JA, Glynn M, et al. 2014. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 55(4):475–482.
  • Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, Lee P, Engel J. 2005. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 46(4):470–472.
  • Frozza RL, Salbego C, Bernardi A, Hoppe JB, Meneghetti A, Battastini AM, Guterres S, Pohlmann A. 2011. Incorporation of resveratrol into lipid-core nanocapsules improves its cerebral bioavailability and reduces the Aβ-induced toxicity. Alzheimer Dement. 7:S114.
  • Gandhi S, Wood NW. 2005. Molecular pathogenesis of Parkinson’s disease. Hum Mol Genet. 14(18):2749–2755.
  • Gao Y, Gu W, Chen L, Xu Z, Li Y. 2008. The role of daidzein-loaded sterically stabilized solid lipid nanoparticles in therapy for cardio-cerebrovascular diseases. Biomaterials. 29(30):4129–4136.
  • Gartziandia O, Herran E, Pedraz JL, Carro E, Igartua M, Hernandez RM. 2015. Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration. Colloids Surf B Biointerfaces. 134:304–313.
  • GBD 2015 Neurological Disorders Collaborator Group. 2017. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 16:877–897.
  • Ghaffari M, Dolatabadi JEN. 2019. Nanotechnology for pharmaceuticals. In: Thomas S, Grohens Y, Pottathara YB, editors. Industrial applications of nanomaterials, micro and nano technologies. Netherlands: Elsevier; p. 475–502.
  • Girault J-A, Greengard P. 2004. The neurobiology of dopamine signaling. Arch Neurol. 61(5):641–644.
  • Gomes dos Reis L, Lee W-H, Svolos M, Moir LM, Jaber R, Windhab N, Young PM, Traini D. 2019. Nanotoxicologic Effects of PLGA nanoparticles formulated with a cell-penetrating peptide: searching for a safe pDNA delivery system for the lungs. Pharmaceutics. 11(1):12.
  • Hardy J. 1999. Pathways to primary neurodegenerative disease. Mayo Clinic Proc. 74(8):835–837.
  • Harshita Barkat MA, Rizwanullah M, Beg S, Pottoo FH, Siddiqui S, Ahmad FJ. 2019. Paclitaxel-loaded nanolipidic carriers with improved oral bioavailability and anticancer activity against human liver carcinoma. AAPS PharmSciTech. 20:87.
  • Hasnain MS, Javed MN, Alam MS, Rishishwar P, Rishishwar S, Ali S, Nayak AK, Beg S. 2019. Purple heart plant leaves extract-mediated silver nanoparticle synthesis: optimization by Box-Behnken design. Mater Sci Eng C. 99:1105–1114.
  • Hassanzadeh P, Arbabi E, Atyabi F, Dinarvand R. 2018. Ferulic acid-loaded nanostructured lipid carriers: a promising nanoformulation against the ischemic neural injuries. Life Sci. 193:64–76.
  • Hassanzadeh P, Atyabi F, Dinarvand R, Dehpour A-R, Azhdarzadeh M, Dinarvand M. 2017. Application of nanostructured lipid carriers: the prolonged protective effects for sesamol in in vitro and in vivo models of ischemic stroke via activation of PI3K signalling pathway. Daru. 25(1):25.
  • Hernando S, Herran E, Figueiro-Silva J, Pedraz JL, Igartua M, Carro E, Hernandez RM. 2018. Intranasal administration of TAT-conjugated lipid nanocarriers loading GDNF for Parkinson’s disease. Mol Neurobiol. 55(1):145–155.
  • Huang H-C, Chang P, Dai X-L, Jiang Z-F. 2012. Protective effects of curcumin on amyloid-β-induced neuronal oxidative damage. Neurochem Res. 37(7):1584–1597.
  • Jafari B, Pourseif MM, Barar J, Rafi MA, Omidi Y. 2019. Peptide-mediated drug delivery across the blood-brain barrier for targeting brain tumors. Expert Opin Drug Deliv. 16(6):583–605.
  • Jaiswal P, Gidwani B, Vyas A. 2016. Nanostructured lipid carriers and their current application in targeted drug delivery. Artif Cells Nanomed Biotechnol. 44(1):27–40.
  • Jankovic J, Stacy M. 2007. Medical management of levodopa-associated motor complications in patients with Parkinson’s disease. CNS Drugs. 21(8):677–692.
  • Javed MN, Alam MS, Waziri A, Pottoo FH, Yadav AK, Hasnain MS, Almalki FA. 2019. QbD applications for the development of nanopharmaceutical products. In: Beg S, Hasnain MS, editors. Pharmaceutical quality by design. London: Academic Press; p. 229–253.
  • Javed MN, Kohli K, Amin S. 2018. Risk assessment integrated QbD approach for development of optimized bicontinuous mucoadhesive limicubes for oral delivery of rosuvastatin. AAPS PharmSciTech. 19(3):1377–1391.
  • Jazuli I, Annu Null Nabi B, Moolakkadath T, Alam T, Baboota S, Ali J. 2019. Optimization of nanostructured lipid carriers of lurasidone hydrochloride using Box-Behnken design for brain targeting: in vitro and in vivo studies. J Pharm Sci. 108(9):3082–3090.
  • Kakkar V, Muppu SK, Chopra K, Kaur IP. 2013. Curcumin loaded solid lipid nanoparticles: an efficient formulation approach for cerebral ischemic reperfusion injury in rats. Eur J Pharm Biopharm. 85(3):339–345.
  • Karantzoulis S, Galvin JE. 2011. Distinguishing Alzheimer’s disease from other major forms of dementia. Expert Rev Neurother. 11(11):1579–1591.
  • Kaushik D. 2016. Baicalein loaded polysorbate 80 nanostructured lipid carriers offered enhanced stability and in vitro drug release. Asian J Pharm. 10(2):S128–S133.
  • Koh SH, Lo EH. 2015. The role of the PI3K pathway in the regeneration of the damaged brain by neural stem cells after cerebral infarction. J Clin Neurol. 11(4):297–304.
  • Kreuter J. 2002. Transport of drugs across the blood-brain barrier by nanoparticles. J Control Release. 161(2):264–273.
  • Kreuter J. 2001. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev. 47(1):65–81.
  • Kumbhar DD, Pokharkar VB. 2013. Engineering of a nanostructured lipid carrier for the poorly water-soluble drug, bicalutamide: Physicochemical investigations. Colloids Surf A. 416:32–42.
  • Kundu P, Das M, Tripathy K, Sahoo SK. 2016. Delivery of dual drug loaded lipid based nanoparticles across the blood-brain barrier impart enhanced neuroprotection in a rotenone induced mouse model of parkinson’s disease. ACS Chem Neurosci. 7(12):1658–1670.
  • Leyva-Gómez G, González-Trujano ME, López-Ruiz E, Couraud P-O, Wekslerg B, Romero I, Miller F, Delie F, Allémann E, Quintanar-Guerrero D. 2014. Nanoparticle formulation improves the anticonvulsant effect of clonazepam on the pentylenetetrazole-induced seizures: behavior and electroencephalogram. J Pharm Sci. 103(8):2509–2519.
  • Li F, Weng Y, Wang L, He H, Yang J, Tang X. 2010. The efficacy and safety of bufadienolides-loaded nanostructured lipid carriers. Int J Pharm. 393(1-2):203–211.
  • Liu Z, Zhang L, He Q, Liu X, Okeke CI, Tong L, Guo L, Yang H, Zhang Q, Zhao H, et al. 2015. Effect of Baicalin-loaded PEGylated cationic solid lipid nanoparticles modified by OX26 antibody on regulating the levels of baicalin and amino acids during cerebral ischemia-reperfusion in rats. Int J Pharm. 489(1-2):131–138.
  • Löscher W, Potschka H. 2005. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci. 6(8):591–602.
  • Loureiro JA, Andrade S, Duarte A, Neves AR, Queiroz JF, Nunes C, Sevin E, Fenart L, Gosselet F, Coelho MAN, et al. 2017. Resveratrol and grape extract-loaded solid lipid nanoparticles for the treatment of Alzheimer’s disease. Molecules. 22(2):277.
  • Lu Y, Huang J, Wang H, Lou X, Liao M, Hong L, Tao R, Ahmed MM, Shan C, Wang X, et al. 2014. Targeted therapy of brain ischaemia using Fas ligand antibody conjugated PEG-lipid nanoparticles. Biomaterials. 35(1):530–537.
  • Luo Y, Chen D, Ren L, Zhao X, Qin J. 2006. Solid lipid nanoparticles for enhancing vinpocetine’s oral bioavailability. J Control Release. 114(1):53–59.
  • Madrid Y, Langer LF, Brem H, Langer R. 1991. New directions in the delivery of drugs and other substances to the central nervous system. Adv Pharmacol. 22:299–324.
  • Marambaud P, Vingtdeux V, Giliberto L, Zhao H, Chandakkar P, Wu Q, Simon JE, Janle EM, Lobo J, Ferruzzi MG, et al. 2010. Resveratrol lowers beta-amyloid accumulation and deposition in vivo by controlling AMPK signaling. Alzheimer’s Dement. 6:S406.
  • Masserini M. 2013. Nanoparticles for brain drug delivery [WWW document]. Int Sch Res Notices. 2013:238428.
  • Mehnert W, Mäder K. 2012. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 64:83–101.
  • Mehnert W, Mäder K. 2001. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 47(2-3):165–196.
  • Mishra S, Sharma S, Javed MN, Pottoo FH, Abul Barkat M, Harshita Null Amir M, Sarfaroz M. 2019. Bioinspired nanocomposites: applications in disease diagnosis and treatment. Pharm Nanotechnol. 7(3):206–209.
  • Misra A, Ganesh S, Shahiwala A, Shah SP. 2003. Drug delivery to the central nervous system: a review. J Pharm Pharm Sci. 6(2):252–273.
  • Moore DJ, West AB, Dawson VL, Dawson TM. 2005. Molecular pathophysiology of Parkinson’s disease. Annu Rev Neurosci. 28(1):57–87.
  • Morsi NM, Ghorab DM, Badie HA. 2013. Brain targeted solid lipid nanoparticles for brain ischemia: preparation and in vitro characterization. Pharm Dev Technol. 18(3):736–744.
  • Moshé SL, Perucca E, Ryvlin P, Tomson T. 2015. Epilepsy: new advances. Lancet. 385(9971):884–898.
  • Moskowitz MA, Lo EH, Iadecola C. 2010. The science of stroke: mechanisms in search of treatments. Neuron. 67(2):181–198.
  • Motawea A, Borg T, El-Gawad AE-GHA. 2018. Topical phenytoin nanostructured lipid carriers: design and development. Drug Dev Ind Pharm. 44(1):144–157.
  • Moustafa RR, Baron J-C. 2009. Pathophysiology of ischaemic stroke: insights from imaging, and implications for therapy and drug discovery. Br J Pharmacol. 153(S1):S44–S54.
  • Mukherjee S, Ray S, Thakur R.S. 2009. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J Pharm Sci. 71(4):349–358.
  • Müller RH, Radtke M, Wissing SA. 2002. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 54 (Suppl 1):S131–S155.
  • Muntimadugu E, Dhommati R, Jain A, Challa VGS, Shaheen M, Khan W. 2016. Intranasal delivery of nanoparticle encapsulated tarenflurbil: a potential brain targeting strategy for Alzheimer’s disease. Eur J Pharm Sci. 92:224–234.
  • Nabi B, Rehman S, Baboota S, Ali J. 2019. Insights on oral drug delivery of lipid nanocarriers: a win-win solution for augmenting bioavailability of antiretroviral drugs. AAPS PharmSciTech. 20(2):60.
  • Nair R, Kumar AC, Priya VK, Yadav CM, Raju PY. 2012. Formulation and evaluation of chitosan solid lipid nanoparticles of carbamazepine. Lipids Health Dis. 11(1):72.
  • Naseri N, Valizadeh H, Zakeri-Milani P. 2015. Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application. Adv Pharm Bull. 5(3):305–313.
  • Neves AR, Queiroz JF, Reis S. 2016. Brain-targeted delivery of resveratrol using solid lipid nanoparticles functionalized with apolipoprotein E. J Nanobiotechnol. 14(1):27.
  • Nigar S, Pottoo FH, Tabassum N, Verma SK, Javed MN. 2016. Molecular insights into the role of inflammation and oxidative stress in epilepsy. JAMPS. 10(1):1–9.
  • Omidi Y, Barar J. 2012. Impacts of blood-brain barrier in drug delivery and targeting of brain tumors. Bioimpacts. 2(1):5–22.
  • Ono K, Hasegawa K, Naiki H, Yamada M. 2004. Curcumin has potent anti-amyloidogenic effects for Alzheimer’s beta-amyloid fibrils in vitro. J Neurosci Res. 75(6):742–750.
  • Pardeshi CV, Belgamwar VS, Tekade AR, Surana SJ. 2013. Novel surface modified polymer-lipid hybrid nanoparticles as intranasal carriers for ropinirole hydrochloride: in vitro, ex vivo and in vivo pharmacodynamic evaluation. J Mater Sci Mater Med. 24(9):2101–2115.
  • Parikh A, Kathawala K, Tan CC, Garg S, Zhou X-F. 2017. Lipid-based nanosystem of edaravone: development, optimization, characterization and in vitro/in vivo evaluation. Drug Deliv. 24(1):962–978.
  • Patel PA, Patil SC, Kalaria DR, Kalia YN, Patravale VB. 2013. Comparative in vitro and in vivo evaluation of lipid based nanocarriers of Huperzine A. Int J Pharm. 446(1-2):16–23.
  • Patel T, Zhou J, Piepmeier JM, Saltzman WM. 2012. Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliv Rev. 64(7):701–705.
  • Perucca E, Tomson T. 2011. The pharmacological treatment of epilepsy in adults. Lancet Neurol. 10(5):446–456.
  • Poovi G, Damodharan N. 2018. Lipid nanoparticles: a challenging approach for oral delivery of BCS Class-II drugs. Future J Pharm Sci. 4(2):191–205.
  • Pottoo FH, Barkat Md A, Harshita Ansari MA, Javed Md N, Sajid Jamal QM, Kamal MA. 2019. Nanotechnological based miRNA intervention in the therapeutic management of neuroblastoma. Seminars Cancer Biol.
  • Pottoo FH, Bhowmik M, Vohora D. 2014. Raloxifene protects against seizures and neurodegeneration in a mouse model mimicking epilepsy in postmenopausal woman. Eur J Pharm Sci. 65:167–173.
  • Pottoo FH, Javed N, Barkat MA, Alam MS, Nowshehri JA, Alshayban DM, Ansari MA. 2018. Estrogen and serotonin: Complexity of interactions and implications for epileptic seizures and epileptogenesis. Curr Neuropharmacol. 17(3):214–231.
  • Pottoo FH, Tabassum N, Darzi MM. 2016. Bromocriptine mesylate protects against status epilepticus and temporal lobe epilepsy: neurobehavioral, histopathological and neurochemical evidences. INDJ. 6(4):1–13.
  • Pottoo FH, Tabassum N, Javed MN, Nigar S, Rasheed R, Khan A, Barkat MA, Alam MS, Maqbool A, Ansari MA, et al. 2018. The synergistic effect of raloxifene, fluoxetine, and bromocriptine protects against pilocarpine-induced status epilepticus and temporal lobe epilepsy. Mol Neurobiol. 56(2):1233–1247.
  • Priano L, Esposti D, Esposti R, Castagna G, De Medici C, Fraschini F, Gasco MR, Mauro A. 2007. Solid lipid nanoparticles incorporating melatonin as new model for sustained oral and transdermal delivery systems. J Nanosci Nanotech. 7(10):3596–3601.
  • Purvin S, Vuddanda PR, Singh SK, Jain A, Singh S. 2014. Pharmacokinetic and tissue distribution study of solid lipid nanoparticles of zidovudine in rats. J Nanotechnol. 2014:1–7.
  • Qian ZM, Ke Y. 2014. Huperzine A: is it an effective disease-modifying drug for Alzheimer’s disease? Front Aging Neurosci. 6:216.
  • Rahman MA, Harwansh RK, Iqbal Z. 2019. Systematic development of sertraline loaded solid lipid nanoparticle (SLN) by emulsification-ultrasonication method and pharmacokinetic study in Sprague-Dawley rats. PNT. 7(2):162–176.
  • Rassu G, Soddu E, Posadino AM, Pintus G, Sarmento B, Giunchedi P, Gavini E. 2017. Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer’s therapy. Colloids Surf B Biointerfaces. 152:296–301.
  • Rodriguez-Nogales C, Noguera R, Patrick C, Blanco-Prieto MJJ. 2019. Therapeutic opportunities in neuroblastoma using nanotechnology. J Pharmacol Exp Ther. 37(3):625–635.
  • Santaguida S, Janigro D, Hossain M, Oby E, Rapp E, Cucullo L. 2006. Side by side comparison between dynamic versus static models of blood-brain barrier in vitro: a permeability study. Brain Res. 1109(1):1–13.
  • Saupe A, Wissing SA, Lenk A, Schmidt C, Müller RH. 2005. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) – structural investigations on two different carrier systems. Biomed Mater Eng. 15(5):393–402.
  • Scalia S, Young PM, Traini D. 2015. Solid lipid microparticles as an approach to drug delivery. Expert Opin Drug Deliv. 12(4):583–599.
  • Schlosshauer B, Steuer H. 2002. Comparative anatomy, physiology and in vitro models of the blood-brain and blood-retina barrier. Curr Med Chem. 2(3):175–186.
  • Scioli Montoto S, Sbaraglini ML, Talevi A, Couyoupetrou M, Di Ianni M, Pesce GO, Alvarez VA, Bruno-Blanch LE, Castro GR, Ruiz ME, et al. 2018. Carbamazepine-loaded solid lipid nanoparticles and nanostructured lipid carriers: physicochemical characterization and in vitro/in vivo evaluation. Colloids Surf B Biointerfaces. 167:73–81.
  • Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. 2011. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 1(1):a006189–a006189.
  • Serteser M, Ozben T, Gumuslu S, Balkan S, Balkan E. 2002. The effects of NMDA receptor antagonist MK-801 on lipid peroxidation during focal cerebral ischemia in rats. Prog Neuro-Psychopharmacol Biol Psychiatry. 26(5):871–877.
  • Shah B, Khunt D, Bhatt H, Misra M, Padh H. 2015. Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: effect on formulation and characterization parameters. Eur J Pharm Sci. 78:54–66.
  • Sharma S, Noushad Javed M, Pottoo F, Arman Rabbani S, Barkat Md Ab H, Sarafroz D, Amir M. 2019. Bioresponse inspired nanomaterials for targeted drug and gene delivery. Pharm Nanotechnol. 7(3):220–233.
  • Shrestha H, Bala R, Arora S. 2014. Lipid-based drug delivery systems. J Pharm. 2014:1–10.
  • Shuiming Z, Dongzhi H, Qineng P, Yan X. 2010. Preparation and entrapment efficiency determination of solid lipid nanoparticles loaded levodopa. Zhongguo Yiyuan Yaoxue Zazhi. 30:1171–1175.
  • Singh R, Lillard JW. 2009. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 86(3):215–223.
  • Sood S, Jain K, Gowthamarajan K. 2013. Curcumin-donepezil–loaded nanostructured lipid carriers for intranasal delivery in an Alzheimer’s disease model. Alzheimer Dement. 9:P299.
  • Su Y, Sinko PJ. 2006. Drug delivery across the blood–brain barrier: why is it difficult? how to measure and improve it? Expert Opin Drug Deliv. 3(3):419–435.
  • Thal LJ, Salmon DP, Lasker B, Bower D, Klauber MR. 1989. The safety and lack of efficacy of vinpocetine in Alzheimer’s disease. J Am Geriatr Soc. 37(6):515–520.
  • Tran TH, Ramasamy T, Cho HJ, Kim YI, Poudel BK, Choi H-G, Yong CS, Kim JO. 2014. Formulation and optimization of raloxifene-loaded solid lipid nanoparticles to enhance oral bioavailability. J Nanosci Nanotech. 14(7):4820–4831.
  • Tsai M-J, Huang Y-B, Wu P-C, Fu Y-S, Kao Y-R, Fang J-Y, Tsai Y-H. 2011. Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. J Pharm Sci. 100(2):547–557.
  • Üner M, Yener G. 2007. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomed. 2:289–300.
  • Uprit S, Kumar Sahu R, Roy A, Pare A. 2013. Preparation and characterization of minoxidil loaded nanostructured lipid carrier gel for effective treatment of alopecia. Saudi Pharm J. 21(4):379–385.
  • Veszelka S, Meszaros M, Kiss L, Kota Z, Pali T, Hoyk Z, Bozso Z, Fulop L, Toth A, Rakhely G, et al. 2017. Biotin and glutathione targeting of solid nanoparticles to cross human brain endothelial cells. Curr Pharm Des. 23(28):4198–4205.
  • Wang B-S, Wang H, Wei Z-H, Song Y-Y, Zhang L, Chen H-Z. 2009. Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer’s disease: an updated meta-analysis. J Neural Transm. 116(4):457–465.
  • Wang JX, Sun X, Zhang ZR. 2002. Enhanced brain targeting by synthesis of 3′,5′-dioctanoyl-5-fluoro-2′-deoxyuridine and incorporation into solid lipid nanoparticles. Eur J Pharm Biopharm. 54(3):285–290.
  • Wavikar P, Pai R, Vavia P. 2017. Nose to brain delivery of rivastigmine by in situ gelling cationic nanostructured lipid carriers: enhanced brain distribution and pharmacodynamics. J Pharm Sci. 106(12):3613–3622.
  • Wohlfart S, Gelperina S, Kreuter J. 2012. Transport of drugs across the blood-brain barrier by nanoparticles. J Control Release. 161(2):264–273.
  • Xu L, Sun J, Lu R, Ji Q, Xu J-G. 2004. Effect of glutamate on inflammatory responses of intestine and brain after focal cerebral ischemia. WJG. 11(5):733–736.
  • Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, et al. 2005. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 280(7):5892–5901.
  • Yusuf M, Khan M, Khan RA, Ahmed B. 2012. Preparation, characterization, in vivo and biochemical evaluation of brain targeted piperine solid lipid nanoparticles in an experimentally induced Alzheimer’s disease model. J Drug Target. 21(3):300–311.
  • Zhao LN, Chiu S-W, Benoit J, Chew LY, Mu Y. 2012. The effect of curcumin on the stability of Aβ dimers. J Phys Chem B. 116(25):7428–7435.
  • Zhao Y-Z, Li X, Lu C-T, Lin M, Chen L-J, Xiang Q, Zhang M, Jin R-R, Jiang X, Shen X-T, et al. 2014. Gelatin nanostructured lipid carriers-mediated intranasal delivery of basic fibroblast growth factor enhances functional recovery in hemiparkinsonian rats. Nanomedicine. 10(4):755–764.
  • Zhong C, He M, Lou K, Gao F. 2017. The application, neurotoxicity, and related mechanism of silica nanoparticles. In: Jiang X, Gao H, editors. Neurotoxicity of nanomaterials and nanomedicine. London: Academic Press; p. 227–257.
  • Zhu CW, Sano M. 2006. Economic considerations in the management of Alzheimer’s disease. Clin Interv Aging. 1(2):143–154.
  • Zhuang C-Y, Li N, Wang M, Zhang X-N, Pan W-S, Peng J-J, Pan Y-S, Tang X. 2010. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm. 394(1–2):179–185.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.